ACTRN12611000364976: Pharmacokinetics and Safety of Solid Oral Posaconazole(SCH 56592) in Subjects at High Risk for Invasive Fungal Infections |
|
|
| Not yet recruiting | 1 | 160 | | | Schering-Plough Pty limited, Schering-Plough Pty limited | High Risk for Invasive Fungal Infection due to:
- Expected neutropenia (low white blood cell count) due to chemotherapy for Acute Myelogenous Leukaemia (AML) or Myelodysplastic Syndrome (MDS), High Risk for Invasive Fungal Infection due to:
- Hematopoietic stem cell transplant (HSCT) recipients undergoing treatment for graft-versus-host disease (GVHD) | | | | |
